Effect of second-generation antipsychotics on cognition: Current issues and future challenges

Expert Review of Neurotherapeutics

Volumn 10, Issue 1, 2010, Pages 43-57

  Hill, S Kristian ^a   Bishop, Jeffrey R ^a   Palumbo, Donna ^b   Sweeney, John A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antipsychotic medication; Biomarker; Cognition; Neuropsychology; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; NEUROPSYCHOLOGY; NONHUMAN; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; NEUROPSYCHOLOGICAL TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 74949104026     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.143     Document Type: Review

References (116)

1. Blanchard JJ, Neale JM. The neuropsychological signature of schizophrenia: generalized or differential deficit? Am. J. Psychiatry 151(1), 40-48 (1994).
2. Saykin AJ, Shtasel DL, Gur RE et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 51(2), 124-131 (1994).
3. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426-445 (1998).
4. Hawkins KA, Keefe RS, Christensen BK et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment study. Schizophr. Res. 105(1-3), 1-9 (2008).
5. Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr. Res. 68(1), 49-63 (2004).
6. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am. J. Psychiatry 156(9), 1336-1341 (1999).
7. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153(3), 321-330 (1996).
8. Sevy S, Davidson M. The cost of cognitive impairment in schizophrenia. Schizophr. Res. 17(1), 1-3 (1995).
9. Blomqvist AG, Leger PT, Hoch JS. The cost of schizophrenia: lessons from an international comparison. J. Ment. Health Policy Econ. 9(4), 177-183 (2006).
10. Hoenberg K, Goetz K. Antipsychotics: Analysis of disease markets and emerging agents. Decision Resources, Inc., Waltham, MA, USA (2006).
11. Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 14(4), 260-282 (1977).
12. Arnsten AF, Cai JX, Steere JC, Goldman-Rakic PS. Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J. Neurosci. 15, 3429-3439 (1995).
13. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287, 2020-2022 (2000).
14. Sawaguchi T, Goldman-Rakic PS. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. 71, 515-528 (1994).
15. Ramaekers JG, Louwerens JW, Muntjewerff ND et al. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin. Psychopharmacol. 19, 209-221 (1999).
16. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157(4), 514-520 (2000).
17. Purdon SE, Woodward N, Lindborg SR, Stip E. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology 169(3-4), 390-397 (2003).
18. Bedard MA, Scherer H, Stip E, Cohen H, Rodriguez JP, Richer F. Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain Cogn. 43, 31-39 (2000).
19. Reilly JL, Harris MS, Keshavan MS, Sweeney JA. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch. Gen. Psychiatry 63(11), 1189-1197 (2006).
20. Blyler CR, Gold JM. Cognitive effects of typical antipsychotic treatment: another look. In: Cognition in Schizophrenia. Sharma T, Harvey PD (Eds). Oxford University Press, NY, USA 241-265 (2000).
21. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol. 98, 367-380 (1989).
22. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr. Bull. 16(3), 477-499 (1990).
23. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol. Bull. 28, 353-366 (1992).
24. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9), 789-796 (1988).
25. Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23(3), 223-239 (2000).
26. Adams B, Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 18(14), 5545-5554 (1998).
27. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28(2), 265-275 (2003).
28. Kargieman L, Santana N, Mengod G, Celada P, Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc. Natl Acad. Sci. USA 104(37), 14843-14848 (2007).
29. Jentsch J. Pre-clinical models of cognitive dysfunction in schizophrenia: new avenues to addressing unmet needs. Clin. Neurosci. Res. 3, 303-315 (2003).
30. Abekawa T, Ito K, Nakagawa S, Nakato Y, Koyama T. Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex. Schizophr. Res. 101(1-3), 84-94 (2008).
31. Toua C, Brand L, Mo Ller M, Emsley RA, Harvey BH. The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-d-aspartate and D(1) receptor binding in rats. Neuroscience DOI:10.1016/j.neuroscience.2009. 10.039 (2009) (Epub ahead of print).
32. Koike H, Ibi D, Mizoguchi H et al. Behavioral abnormality and pharmacologic response in social isolation-reared mice. Behav. Brain Res. 202(1), 114-121 (2009).
33. Li N, Wu X, Li L. Chronic administration of clozapine alleviates reversal-learning impairment in isolation-reared rats. Behav. Pharmacol. 18(2), 135-145 (2007).
34. Barr AM, Powell SB, Markou A, Geyer MA. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 51(3), 457-465 (2006).
35. Cilia J, Cluderay JE, Robbins MJ et al. Reversal of isolation-rearing-induced PPI deficits by an a7 nicotinic receptor agonist. Psychopharmacology (Berl.) 182(2), 214-219 (2005).
36. Kinkead B, Dobner PR, Egnatashvili V, Murray T, Deitemeyer N, Nemeroff CB. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J. Pharmacol. Exp. Ther. 315(1), 256-264 (2005).
37. Abdul-Monim Z, Reynolds GP, Neill JC. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J. Psychopharmacol. 17(1), 57-66 (2003).
38. Amitai N, Semenova S, Markou A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology 193(4), 521-537 (2007).
39. He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-X-sub(L)/ Bax ratio in the posterior cingulate cortex in rats. Behav. Brain Res. 168(2), 236-242 (2006).
40. He J, Yang Y, Yu Y, Li X, Li XM. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav. Brain Res. 172(1), 39-45 (2006).
41. Hagiwara H, Fujita Y, Ishima T et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT-sub(1A) receptors. Eur. Neuropsychopharmacol. 18(6), 448-454 (2008).
42. Dunn MJ, Killcross S. Clozapine, SCH 23390 and α-flupenthixol but not haloperidol attenuate acute phencyclidine-induced disruption of conditional discrimination performance. Psychopharmacology 190(4), 403-414 (2007).
43. Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 1063(1), 32-89 (2005).
44. He J, Yang Y, Xu H, Zhang X, Li XM. Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology 30(8), 1511-1520 (2005).
45. Bardgett ME, Griffith MS, Foltz RF, Hopkins JA, Massie CM, O'Connell SM. The effects of clozapine on delayed spatial alternation deficits in rats with hippocampal damage. Neurobiol. Learning Memory 85(1), 86-94 (2006).
46. Hou Y, Wu CF, Yang JY, Guo T. Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(8), 1486-1495 (2006).
47. Matsumoto M, Shikanai H, Togashi H et al. Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-mPFC pathway of anesthetized rats. Brain Res. 1195, 50-55 (2008).
48. Elsworth JD, Jentseh JD, Morrow BA, Roth RH, Redmond DE Jr. Clozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine. Neuropsychopharmacology 33(3), 491-496 (2008).
49. Sur C, Mallorga PJ, Wittmann M et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d- aspartate receptor activity. Proc. Natl Acad. Sci. USA 100(23), 13674-13679 (2003).
50. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry 36(11), 717-725 (1994).
51. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry 55(Suppl. B), 82-87 (1994).
52. Green MF, Marshall BD Jr, Wirshing WC et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry 154(6), 799-804 (1997).
53. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bull. 25(2), 233-255 (1999).
54. Green MF. Recent studies on the neurocognitive effects of second-generation antipsychotic medications. Curr. Opin. Psychiatry 15(1), 25-29 (2002).
55. Meltzer HY, McGurk SR. Effect of atypical antipsychotic drugs on cognitive function in schizophrenia. In: The treatment of schizophrenia: status and emerging trends. Brenner HD, Boker W, Genner R (Eds). Hogrefe & Huber Publishers, Ashland, OH, USA, 49-59 (2001).
56. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25(2), 201-222 (1999).
57. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8(3), 457-472 (2005).
58. Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol. Psychiatry 51(12), 969-971 (2002). • Presents the indirect action hypothesis that the beneficial cognitive effects of second-generation antipsychotics (SGAs) observed in early studies were merely a release from the adverse effects of first-generation antipsychotics.
59. Perlick D, Stastny P, Katz I, Mayer M, Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia. Am. J. Psychiatry 143(2), 230-232 (1986).
60. Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry 139(11), 1460-1462 (1982).
61. Purdon SE, Jones BDW, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry 57(3), 249-258 (2000).
62. Keefe RSE, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry 161(6), 985-995 (2004).
63. Keefe RS, Seidman LJ, Christensen BK et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol. Psychiatry 59(2), 97-105 (2006).
64. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am. J. Psychiatry 162(10), 1888-1895 (2005).
65. Thornton AE, Van Snellenberg JX, Sepehry AA, Honer WG. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. Psychopharmacology 20(3), 335-346 (2006).
66. Goldberg TE, Goldman RS, Burdick KE et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch. Gen. Psychiatry 64(10), 1115-1122 (2007). •• Provides empirical support for the notion that treatment-related cognitive improvements may not be greater than expected practice effects.
67. Albus M, Hubmann W, Mohr F et al. Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. Eur. Arch. Psychiatry Clin. Neurosci. 256(7), 442-451 (2006).
68. Hill SK, Reilly JL, Harris MS et al. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr. Res. 113(2-3), 167-175 (2009).
69. Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J. Clin. Psychiatry 70(5), 717-729 (2009).
70. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr. Res. 89(1-3), 211-224 (2007). •• This is a meta-analysis that separately evaluates open-label and randomized double-blind controlled trials. Perhaps more interesting is an upcoming meta-analysis from this group, which includes Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) findings and is expected to report a small mean effect size (∼0.10) for the beneficial cognitive effects of SGAs.
71. Chapman LJ, Chapman JP. The measurement of differential deficit. J. Psychiatry Res. 14, 303-311 (1978).
72. Strauss ME. Demonstrating specific cognitive deficits: a psychometric perspective. J. Abnorm. Psychol. 110(1), 6-14 (2001).
73. Dickinson D, Ragland JD, Gold JM, Gur RC. General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol. Psychiatry 64(9), 823-827 (2008). •• Presents the hypothesis that rather than tapping into domain-specific processes, clinical neuropsychological tests converge on a generalized cognitive factor.
74. Hill SK, Sweeney JA, Hamer RM et al. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J. Int. Neuropsychol. Soc. 14(2), 209-221 (2008). • Uses clinical trial data to show that neuropsychological measures primarily assess a generalized cognitive factor, both prior to and after treatment.
75. Harris MS, Reilly JL, Keshavan MS, Sweeney JA. Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia. Psychol. Med. 36(4), 485-494 (2006).
76. Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 64(6), 633-647 (2007).
77. Davidson M, Galderisi S, Weiser M et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 166(6), 675-682 (2009).
78. Keefe RS, Sweeney JA, Gu H et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 164(7), 1061-1071 (2007). •• Reports Comparison of Atypicals for First-Episode Psychosis (CAFE) findings regarding cognitive outcomes.
79. Keefe RS, Harvey PD, Goldberg TE et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr. Res. 102(1-3), 108-115 (2008).
80. Dickinson D, Ragland JD, Calkins ME, Gold JM, Gur RC. A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr. Res. 85(1-3), 20-29 (2006).
81. Freedman R, Olincy A, Buchanan RW et al. Initial Phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 165(8), 1040-1047 (2008).
82. Liberman RP, Gutkind D, Mintz J et al. Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. Comprehensive Psychiatry 43(6), 469-473 (2002).
83. Manschreck TC, Redmond DA, Candela SF, Maher BA. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J. Neuropsych. Clin. Neurosci. 11(4), 481-489 (1999).
84. Hofer A, Baumgartner S, Bodner T et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur. Psychiatry 20(5-6), 395-402 (2005).
85. Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophr. Res. 63(1-2), 97-101 (2003).
86. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 65(7), 932-939 (2004).
87. Perlick DA, Rosenheck RA, Kaczynski R, Collins J, Bingham S. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr. Res. 99(1-3), 192-199 (2008).
88. Norman RM, Malla AK, Cortese L et al. Symptoms and cognition as predictors of community functioning: a prospective analysis. Am. J. Psychiatry 156(3), 400-405 (1999).
89. Dickerson F, Boronow JJ, Ringel N, Parente F. Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. Schizophr. Res. 37(1), 13-20 (1999).
90. Swartz MS, Perkins DO, Stroup TS et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 164(3), 428-436 (2007).
91. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18(13), 877-893 (2004).
92. Lipkovich IA, Deberdt W, Csernansky JG, Sabbe B, Keefe RS, Kollack-Walker S. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry 9, 44 (2009).
93. Velligan DI, Kern RS, Gold JM. Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr. Bull. 32(3), 474-485 (2006).
94. Harvey PD, Keefe RS, Patterson TL, Heaton RK, Bowie CR. Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. J. Clin. Exp. Neuropsychol. 31(4), 462-471 (2009).
95. Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol. 63(10), 1372-1376 (2006).
96. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr. Bull. 34(5), 944-961 (2008). •• One of the few bottom-up, translational neuroscience approaches capable of leading to effective procognitive pharmacological treatments.
97. Whittington MA, Traub RD, Kopell N, Ermentrout B, Buhl EH. Inhibition-based rhythms: experimental and mathematical observations on network dynamics. Int. J. Psychophysiol. 38(3), 315-336 (2000).
98. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6(4), 312-324 (2005).
99. Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical g synchrony and cognitive control in schizophrenia. Proc. Natl Acad. Sci. USA 103(52), 19878-19883 (2006).
100. Lewis DA, Cho RY, Carter CS et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 165(12), 1585-1593 (2008).
101. Hill SK, Reilly JL, Harris MS, Khine T, Sweeney JA. Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. Schizophr. Bull. 34(3), 494-506 (2007). •• This is a unique report directly comparing the sensitivity of oculomotor and neuropsychological measures to antipsychotic treatments.
102. Light GA, Geyer MA, Clementz BA, Cadenhead KA, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry 157(5), 767-771 (2000).
103. Reilly JL, Lencer R, Bishop JR, Keedy S, Sweeney JA. Pharmacological treatment effects on eye movement control. Brain Cogn. 68(3), 415-435 (2008). •• A comprehensive review of the beneficial and adverse effects of antipsychotics on oculomotor paradigms.
104. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch. Gen. Psychiatry 62(2), 127-136 (2005).
105. Keedy SK, Rosen C, Khine T, Rajarethinam R, Janicak PG, Sweeney JA. An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia. Psychiatry Res. 172(1), 16-23 (2009).
106. Hajos M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol. Sci. 27(7), 391-398 (2006).
107. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajos M. Neurophysiological biomarkers for drug development in schizophrenia. Nat. Rev. Drug Discov. 7(1), 68-83 (2008).
108. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40(5), 881-884 (2003).
109. Tamminga CA. The neurobiology of cognition in schizophrenia. J. Clin. Psychiatry 67(Suppl. 9), 9-13 (2006).
110. Weinberger DR, Egan MF, Bertolino A et al. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry 50(11), 825-844 (2001).
111. Bertolino A, Caforio G, Blasi G et al. Interaction of COMT Val108/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 161(10), 1798-1805 (2004).
112. Woodward ND, Jayathilake K, Meltzer HY. COMT Val108/158Met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res. 90(1-3), 86-96 (2007).
113. Hill SK, Keshavan MS, Thase ME, Sweeney JA. Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression. Am. J. Psychiatry 161(6), 996-1003 (2004).
114. Reilly JL, Harris MSH, Keshavan MS, Sweeney JA. Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia. Biol. Psychiatry 57(2), 145-154 (2005).
115. Reilly JL, Harris MS, Khine TT, Keshavan MS, Sweeney JA. Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia. Biol. Psychiatry 63(8), 776-783 (2008).
116. Harris MS, Wiseman CL, Reilly JL, Keshavan MS, Sweeney JA. Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia. Neuropsychopharmacology 34(2), 468-476 (2009).